

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850



CENTER FOR MEDICARE

DATE: March 07, 2014

TO: All Part D Plan Sponsors

FROM: Tracey McCutcheon, MHSA, MBA, Acting Director
Medicare Drug Benefit and C&D Data Group
Jeffrey Kelman, M.D., Chief Medical Officer

SUBJECT: Update on Antifungal Medication Coverage Determination Requests following
2012 Meningitis Outbreak

On October 16, 2012, the Centers for Medicare & Medicaid Services (CMS) issued guidance instructing Part D sponsors to expedite all coverage determination requests for voriconazole, and other appropriate antifungal medications, due to the meningitis outbreak associated with contaminated steroid products produced by the New England Compounding Center (NECC). We have received questions about the current status of this policy and when it will end. We clarify that at this time we no longer expect Part D sponsors to continue to expedite all coverage determinations requests for these medications and, therefore, sponsors may resume normal coverage determination procedures.

For further questions on this guidance, please contact Craig Miner at (410) 786-7937 or craig.miner@cms.hhs.gov